Neurocrine Biosciences (NBIX) Cash from Investing Activities (2010 - 2026)

Neurocrine Biosciences' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$506.2 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 3664.79% year-over-year to -$506.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$784.8 million (down 1262.5% YoY) and the FY2025 annual result came in at -$264.4 million, down 108.52% from the prior year.
• Cash from Investing Activities was -$506.2 million for Q1 2026 at Neurocrine Biosciences, down from -$52.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $31.4 million in Q2 2022 and bottomed at -$506.2 million in Q1 2026.
• A 5-year average of -$90.7 million and a median of -$55.0 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 134.58% — and 2026, when it plunged 3664.79%.
• Neurocrine Biosciences' Cash from Investing Activities stood at -$115.6 million in 2022, then tumbled by 74.57% to -$201.8 million in 2023, then jumped by 66.15% to -$68.3 million in 2024, then climbed by 22.55% to -$52.9 million in 2025, then slumped by 856.9% to -$506.2 million in 2026.
• Business Quant data shows NBIX's Cash from Investing Activities at -$506.2 million in Q1 2026, -$52.9 million in Q4 2025, and -$196.7 million in Q3 2025.